Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2016 16:05 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Second Quarter 2016 Financial Results

EMERYVILLE, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the second quarter of 2016. “We are pleased with...
June 29, 2016 16:05 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

EMERYVILLE, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will...
June 22, 2016 06:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson’s Disease and Movement Disorders

EMERYVILLE, Calif., June 22, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced additional data from its Phase 3 clinical program of ADS-5102 (amantadine HCl)...
June 13, 2016 08:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Positive Results from its Phase 2 Proof-of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis (MS) Patients

EMERYVILLE, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive findings from its Phase 2 proof-of-concept study designed to evaluate...
May 16, 2016 18:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 20th International Congress of Parkinson’s and Movement Disorders

EMERYVILLE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that data from EASE LID and EASE LID 2, trials from the company’s Phase 3...
May 10, 2016 16:05 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports First Quarter 2016 Financial Results

EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the first quarter of 2016. Adamas ended the...
May 06, 2016 17:40 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) Adamas today announced that its new General Counsel and Corporate Secretary, Jennifer Rhodes, received...
April 28, 2016 07:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Positive Top-line Results from its Phase 3 EASE LID 3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients with Parkinson’s Disease

Third Randomized Clinical Trial Meets Primary and Key Secondary Endpoints Conference Call and Webcast Today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) EMERYVILLE, Calif., April 28, 2016 ...
April 27, 2016 20:08 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Host Conference Call and Webcast to Provide Company Update

EMERYVILLE, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will...
April 19, 2016 20:45 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Presents Positive Findings From the Phase 3 EASE LID Clinical Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) Associated with Parkinson’s Disease at the American Academy of Neurology Annual Meeting

Anti-dyskinetic Effect Consistent Across Primary and Secondary Outcome Measures EMERYVILLE, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced...